An Important Milestone for Regenxbio Treatment of Wet AMD

Regenxbio Good News for wet AMD
On January 10, 2022,  Regenxbio Inc. (RGNX) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (wet AMD).

RGX-314 is being investigated as a potential one-time gene therapy for . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.